Stefanie Bailey

Congrats @rishabrama and collaborators @MGBneurosurgery on our work developing Meso-CAR T cells for refractory meningiomas, published this week @NeuroOnc! doi.org/10.1093/neuonc…

Check out our new paper in Hepatology on how myeloid cells limit #immunotherapy in preclinical #cholangiocarcinoma models! Disease site matters! Collaborative effort with @Chrystal_Paulos and many others @WinshipAtEmory @KimmelCancerCtr @VanderbiltU pubmed.ncbi.nlm.nih.gov/40590857/

Analyzing scRNAseq data from CAR T cell infusion products, Supper and Donner et al. found that VEGFR1 was expressed in 41BB.z CAR T cells and associated negatively with treatment response. bit.ly/3FW0PIi

I always love the schematics and overviews from @ACIR_org. Thank you for providing this nice summary of our most recent work on IFNg-resistant CAR-T cells 🧫

#ScienceSaturday ❓How can we help CAR T cells survive longer and fight tumors more effectively? ➡️ In this study, Bailey et al. found that deleting the interferon-γ receptor (IFN-γR) in CAR T cells prevents IFN-γ–induced cell death, especially in CD28-based CARs, leading to…

Amazing talk by Dr. Ayana Ruffin ⁦@AyanaTRuffin⁩ ⁦@WinshipAtEmory⁩ on the importance of CD2 in adoptive immunotherapy of cancer. It’s a T:B thing. #2025SIS⁩ on the UVA campus.

Had the opportunity to chair the session for rockstar speakers @Chrystal_Paulos and @AyanaTRuffin at #2025SIS today. Love seeing my mentor-for-life and her trainees crush it! Th17 cells and CD2 for the win! 🧬

Teaching this crew to make virus in the ultracentrifuge today after they successfully cloned and generated their own CAR plasmids 🧬🦠 Super proud mentor 🥹

Cancer escapes immunotherapies by mutating its surface. This means even groundbreaking #CARTCell therapies fail too often because of cancer resistance. But what if we could use #GenerativeAI to design CAR-T with de novo binders faster and smarter, targeting even resistant tumors?…

Excited to report our newest preprint is now available! Herein we find that expanding human CART cells with an AMPK agonist rewires their metabolism and significantly improves anti-leukemia survival in an xenograft model. Check it out! @PedsHemeOncPGH @Byersdoc_BMT

Today was the day we walked for Nora ❤️ Thank you to everyone who contributed to this effort to end childhood cancer, whether it be physically or financially. I’m so blessed to call this team mine! Now the hard work continues in the lab.

We are hiring! Apply for this postdoc position in @Pauloslab. We seek to work with immunologists eager to build our cellular therapy program. We generate novel CAR, TIL and TCR cell products to kill solid tumors! faculty-emory.icims.com/jobs/132570/po…

I am proud, pleased, and relieved to announce that the Schenkel Lab’s first paper is officially published @J_Immunol! This has been a labor of love and I think will be an useful for many in the field! journals.aai.org/jimmunol/artic… 1/n

#FollowFriday Chrystal Paulos is director of translational research and associate professor at the Department of Surgery and Microbiology and Immunology @EmoryMedicine. She's an innovative tumor #immunologist who has mentored many young scientists. Follow her @Chrystal_Paulos.

I am incredibly excited to announce the opening of the @TyMillerLab at @CWRUSOM and @UHhospitals in Cleveland! My lab will be dedicated to creating effective immunotherapies for brain tumor patients. Learn more at our freshly minted website - tymillerlab.org

Check out this must-read commentary from my good friend @EliDarnellMD and my mentor @MarcelaMaus on a study investigating the impact of TME on CART efficacy within the ZUMA7 trial doi.org/10.1016/j.xcrm… @MGHCancerCenter #WeekendReading

The clinical data from one of my favorite bench-to-bedside studies from the Maus lab is out! Congrats to @BryanDChoi, @MarcelaMaus and the team. Excited to see how this informs future cell therapies for patients with glioblastoma.

Excited to present in Miami today at Spring ⁦@sitcancer⁩ on work from my former MSTP student Dr ⁦@GuillermoORang1⁩ and ⁦@PaulosLab⁩ team.